Seelos Therapeutics (NSDQ:SEEL) announced today that it partnered with AptarGroup (NYSE:ATR) for the Bidose liquid system device.
The agreement includes the co-exclusive use and supply of Aptar Pharma’s Bidose device for the delivery of Seelos’ intranasal ketamine product candidate, SLS-002, for treating suicidality, depression and post-traumatic stress disorder (PTSD).
Get the full story at our sister site, Drug Delivery Business News.